LGAIMEMar 9, 2025

Censoring-Aware Tree-Based Reinforcement Learning for Estimating Dynamic Treatment Regimes with Censored Outcomes

arXiv:2503.06690v1h-index: 1
Originality Incremental advance
AI Analysis

This work addresses the challenge of personalized treatment strategies in healthcare, particularly for sequential decisions with censored data, representing an incremental advance in clinical decision-making.

The paper tackled the problem of estimating optimal dynamic treatment regimes with censored survival outcomes by proposing CA-TRL, a framework that enhanced tree-based reinforcement learning with AIPW and censoring-aware modifications, and demonstrated its effectiveness by outperforming the ASCL method in simulations and real-world epilepsy data, achieving improvements in restricted mean survival time and decision-making accuracy.

Dynamic Treatment Regimes (DTRs) provide a systematic approach for making sequential treatment decisions that adapt to individual patient characteristics, particularly in clinical contexts where survival outcomes are of interest. Censoring-Aware Tree-Based Reinforcement Learning (CA-TRL) is a novel framework to address the complexities associated with censored data when estimating optimal DTRs. We explore ways to learn effective DTRs, from observational data. By enhancing traditional tree-based reinforcement learning methods with augmented inverse probability weighting (AIPW) and censoring-aware modifications, CA-TRL delivers robust and interpretable treatment strategies. We demonstrate its effectiveness through extensive simulations and real-world applications using the SANAD epilepsy dataset, where it outperformed the recently proposed ASCL method in key metrics such as restricted mean survival time (RMST) and decision-making accuracy. This work represents a step forward in advancing personalized and data-driven treatment strategies across diverse healthcare settings.

Foundations

The foundational work for this paper's niche, ranked by how specifically the neighbourhood builds on it — not by global fame.

Your Notes